Hepatobiliary effects and safety of tirzepatide: A systematic review and meta-analysis

Affiliations

¹ Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh.
² Department of Endocrinology, CEDAR Superspeciality Healthcare, New Delhi, India.
³ Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India.
⁴ Department of Endocrinology and Diabetes, Medanta the Medicity Hospital, Gurugram, India.
⁵ Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
⁶ Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust & Manchester Metropolitan University, Preston, UK.

A B M Kamrul-Hasan et al. Diabetes Obes Metab. 2024 Dec.

. 2024 Dec;26(12):6074-6079.

doi: 10.1111/dom.15948. Epub 2024 Sep 13.

¹ Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh.
² Department of Endocrinology, CEDAR Superspeciality Healthcare, New Delhi, India.
³ Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India.
⁴ Department of Endocrinology and Diabetes, Medanta the Medicity Hospital, Gurugram, India.
⁵ Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
⁶ Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust & Manchester Metropolitan University, Preston, UK.

No abstract available

Keywords: alanine aminotransferase; aspartate aminotransferase; cholecystitis; cholelithiasis; hepatic fat content; tirzepatide.

References

1. García‐Compeán D, Orsi E, Kumar R, et al. Clinical implications of diabetes in chronic liver disease: diagnosis, outcomes and management, current and future perspectives. World J Gastroenterol. 2022;28:775‐793.
1. Al‐Mrabeh A. Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us? Cardiovasc Endocrinol Metab. 2020;9:132‐142.
1. Ghosal S, Datta D, Sinha B. A meta‐analysis of the effects of glucagon‐like‐peptide 1 receptor agonist (GLP1‐RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 2021;11:22063.
1. Dutta D, Kumar M, Shivaprasad KS, Kumar A, Sharma M. Impact of semaglutide on biochemical and radiologic measures of metabolic‐dysfunction associated fatty liver disease across the spectrum of glycaemia: a meta‐analysis. Diabetes Metab Syndr. 2022;16:102539.
1. Kuchay MS, Krishan S, Mishra SK, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D‐LIFT trial). Diabetologia. 2020;63:2434‐2445.